Twist Q3 revenues rise 60%

By LabPulse.com staff writers

August 5, 2022 -- Twist Bioscience on Friday reported a 60% year-over-year rise in fiscal Q3 revenues. For the three months ended June 30, the synthetic DNA product developer reported revenues of $56.1 million compared to $35.0 million for the same period of fiscal year 2021, beating analysts’ average estimate of $51.5 million.

Twist's Q3 net loss was $60.5 million, or $1.08 per share, compared to $40 million ($.82 per share) for the same period of fiscal 2021.

For fiscal year 2022, Twist anticipates revenues of approximately $203 million, an increase from its previous guidance of $191 million to $199 million.

Among recent business highlights, the firm shipped products to approximately 1,900 customers in Q3, compared to approximately 1,800 in Q3 2021.

Twist also shipped approximately 163,000 genes during the third quarter compared with approximately 107,000 in the third quarter of fiscal 2021; additionally, it launched two human monkeypox synthetic DNA controls, expanding the firm's portfolio of synthetic controls and reference standards.

As of June 30, the company had $527.6 million in cash, cash equivalents, and investments.

In Friday afternoon trading on the Nasdaq, Twist shares were up more than 10% at $51.63.

DNAnexus, Twist Bioscience partner on NGS data analysis
DNAnexus and Twist Bioscience on Wednesday announced a collaboration aimed at reducing the time to design, validate, and commercialize next-generation...
Twist releases NGS panel for coronavirus research
Twist Bioscience has made available for research purposes its target enrichment next-generation sequencing (NGS) panels for detecting and characterizing...
Twist Bioscience, Sophia Genetics partner on NGS, DNA analysis
Twist Bioscience and Sophia Genetics are working together on next-generation sequencing (NGS) and DNA analysis powered by artificial intelligence.

Copyright © 2022 LabPulse.com

Last Updated mp 8/5/2022 11:47:56 AM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current